Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.04 USD
Change Today +0.002 / 6.06%
Volume 159.2K
CORX On Other Exchanges
Symbol
Exchange
OTC US
As of 5:19 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

cortex pharmaceuticals inc (CORX) Snapshot

Open
$0.03
Previous Close
$0.03
Day High
$0.04
Day Low
$0.03
52 Week High
10/7/14 - $0.09
52 Week Low
05/21/15 - $0.02
Market Cap
14.5M
Average Volume 10 Days
253.2K
EPS TTM
$-0.02
Shares Outstanding
414.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORTEX PHARMACEUTICALS INC (CORX)

Related News

No related news articles were found.

cortex pharmaceuticals inc (CORX) Related Businessweek News

No Related Businessweek News Found

cortex pharmaceuticals inc (CORX) Details

Cortex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of respiratory disorders. It offers novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression, and other brain-mediated breathing disorders. The company has two drug platforms comprising ampakines that act as positive allosteric modulators of AMPA glutamate receptors; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. It offers various ampakines in both oral and injectable form for the treatment of drug induced respiratory depression caused by opiates and anesthetics. The company’s lead ampakine, CX1739, has completed Phase I clinical studies for drug-induced respiratory depression, as well as is in Phase I clinical studies for central sleep apnea in chronic opioid users and chronic heart failure. It is also developing dronabinol, which has completed Phase I clinical study for the treatment of obstructive sleep apnea; and CX1942, a soluble ampakine, which has completed preclinical stage for the emergency treatment of drug-induced respiratory depression. The company was founded in 1987 and is based in Glen Rock, New Jersey.

1 Employees
Last Reported Date: 03/30/15
Founded in 1987

cortex pharmaceuticals inc (CORX) Top Compensated Officers

Chief Financial Officer, Vice President and D...
Total Annual Compensation: --
Vice President, Treasurer, Secretary and Dire...
Total Annual Compensation: --
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

cortex pharmaceuticals inc (CORX) Key Developments

Cortex Pharmaceuticals, Inc. Announces Management Changes

Cortex Pharmaceuticals, Inc. announced that On August 18, 2015, the company entered into a contract hiring James S. J. Manuso, as its new President and Chief Executive Officer. Dr. Manuso is being hired for an initial three year term. Dr. Manuso is the former Chairman of the Board of Directors and Chief Executive Officer of Astex Pharmaceuticals, Inc., having served in such positions from July 2011 through October 2013. Dr. Manuso currently serves on the board of directors of privately-held KineMed, Inc. Dr. Manuso is also being appointed as a director of the company, as of August 18, 2015, filling an existing vacancy on the Board. In addition to being a member of the Board, he has agreed to serve as Vice Chairman, a non-executive position. It has not yet been determined on which committees of the Board Dr. Manuso will serve. On August 18, 2015, the company, concurrently with the hiring of James S. J. Manuso as the new President and Chief Executive Officer of the company, accepted the resignation of Dr. Arnold S. Lippa, as President and Chief Executive Officer. Dr. Lippa will remain the company's Executive Chairman and a member of the Board. Also on August 18, 2015, Dr. Lippa was named Chief Scientific Officer of the company, and the company entered into a contract with him in that capacity.

Cortex Pharmaceuticals, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 10:30 AM

Cortex Pharmaceuticals, Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 10:30 AM. Venue: Time Warner Center, New York, United States.

Cortex Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Cortex Pharmaceuticals, Inc. filed its 10-K on Mar 30, 2015 for the period ending Dec 31, 2014. In this report its auditor, Haskell & White LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORX:US $0.04 USD +0.002

CORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $79.80 USD -2.55
Novartis AG SFr.91.70 CHF -3.00
Pfizer Inc $31.36 USD -0.86
View Industry Companies
 

Industry Analysis

CORX

Industry Average

Valuation CORX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 97.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 97.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORTEX PHARMACEUTICALS INC, please visit www.cortexpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.